In an interview with Rica Bhattacharyya and Vikas Dandekar, Shaw detailed how the merger removes the holdco overhang, strengthens monetary metrics, and gives well timed exits for traders equivalent to True North, Tata Capital and Viatris. She additionally outlined how the mixed entity—distinctive for its interchangeable biosimilar insulins and generic GLP-1 peptides—will unlock synergies throughout manufacturing, R&D, gadgets and industrial footprints.
ET was the primary to report on November 13 that Biocon had appointed Morgan Stanley to judge the perfect value-creation possibility, together with a merger and share swap.
Permitting extra cash move
The Biocon board has accepted elevating extra capital of as much as ₹4,500 crore ($500 million) by means of a professional institutional placement (QIP), which will probably be largely utilised in the direction of the money part payable to Viatris, whose international biosimilars enterprise was acquired by Biocon Biologics in 2022.
Edited excerpts of the interview:
What was the rationale behind the share swap determination, since you had been contemplating different choices like an IPO as nicely?We had earlier anticipated to take BBL to an IPO as a result of we thought that was one of the simplest ways of giving an exit to the traders. However the markets took the Viatris acquisition negatively and hammered Biocon’s valuation due to the acquisition debt. We needed to additionally take a look at a holdco low cost. The mixture of the 2 elements fully devalued Biocon’s shares. That, by extension, additionally affected BBL’s intrinsic worth.
So, we requested the query that even when we take BBL public, will it end in worth unlocking? Then we appointed Morgan Stanley to judge all choices—IPO, merger, share swap—and determined to purchase out the impartial stakeholders in Biologics and do a share swap. That mechanically makes BBL an entirely owned subsidiary of Biocon after which it turns into a mixed enterprise.
That manner, we’ll do away with the holdco low cost, be capable of see a really strong monetary stability sheet, and the entire metrics change—the debt-to-Ebitda ratio has dropped from 4.3 in 2020 to 2.5 right this moment and we’re anticipated to go down even additional subsequent fiscal. It places us in a really robust place, permitting free money move. We now have additionally retired the structural fairness debt of Kotak and Goldman Sachs and others, which is able to release one other ₹300 crore of provisioning curiosity.
The governance council and integration administration committee have been introduced. What are the quick high three priorities for these our bodies over the subsequent 90 days?
First is to learn how the brand new organisation appears to be like. Though it’s a very complementary match, they’re additionally very completely different, as a result of the manufacturing of small molecules could be very completely different from manufacturing of biologics. However divisions like logistics, IT and a few others don’t want duplication.
We’ll first take a look at the organisation construction and the way to slot in some individuals. We’ll wish to accommodate everybody—their roles is not going to change, however the organisation construction will change a bit. On the high stage, we can’t have two CEOs and that’s why we determined that Shreehas Tambe will take over as CEO and MD as a result of he’s operating the extra complicated and bigger enterprise. However Siddharth Mittal, the present Biocon CEO, is a good chief and we’ll discover a good management function for him within the firm.
If not for the investor strain and the market’s concern about acquisition debt, would you continue to mix the 2 companies?
It’s not for the investor strain. We needed to discover an exit for our traders in Biologics. It was not about Biocon however about our fairness traders in Biologics. We had Serum, Tata Capital, True North and Viatris. All of them needed to be supplied an exit at some stage.
Serum had no possibility however to attend as a result of they’d no clause on a specified date. However so far as Viatris was involved, we had a date of 2030, and for True North and Tata Capital it was 2026. So, there was an urgency in taking this determination—both we had to purchase them out or give them an exit. We thought let’s take a look at a liquidity occasion that addresses all this.
Everybody has benefitted from this merger. Viatris has obtained a five-year accelerated liquidity occasion. True North and Tata Capital obtained what they needed as a result of they had been invested at a sure stage, and we truly obtained a valuation of $5.5-billion swap ratio. If we had gone for an IPO, the debt overhang would in all probability have lowered the worth. Given all that, that is the most suitable choice.
What are the most important advantages from this integration? The mixed entity is positioned strongly as a unified international participant throughout each biosimilars and generics, however on the identical time each are very completely different companies…
The truth that we’re an Ebitda enchancment ratio tells us that there will probably be good contributions from synergies as nicely. In three months, we’ll know what these quantifiable advantages are. We are actually targeted on the mixed enterprise.
General, we count on robust progress, particularly in biosimilars. With the brand new launches we’ve had, we count on strong efficiency. We even have a singular worth proposition as a result of we’re the one firm globally that has biosimilar interchangeable insulins and a portfolio of generic GLP-1s.
This places us in a really robust place as a result of we’ve end-to-end capabilities. Whether or not it’s manufacturing drug substances, drug merchandise or gadgets, all the pieces is inside and built-in. We don’t have to outsource, and we’ve scale—one thing many corporations lack.
Does the combination speed up Biocon’s method to launches in main markets just like the US, Europe and Japan?
It is going to actually speed up our method to launches, particularly in markets just like the US. We’re very mature in our industrial footprint in the case of biosimilars, which is essentially the most complicated enterprise. Even in rising markets, BBL has its personal presence in lots of key areas the place Biocon earlier relied on companions.
From that perspective, controlling the enterprise in key markets could be very engaging. A mixed portfolio of biosimilars and generics can also be extraordinarily helpful. We are able to speed up launches, develop the enterprise and derive super synergies. The 2 companies are extremely complementary.
